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Background: Recent studies have reported differential morphologic characteristics of
neointimal tissue after stenting by optical coherence tomography (OCT). The aim of
this study was to investigate the clinical implication of the characteristics of neo-
intimal hyperplasia after stent implantation.
Methods: A total of 492 lesions in 447 patients treated with stents from the Yonsei
OCT registry were divided into two groups based on the neointimal characteristics;
heterogeneous group including thin-cap ﬁbroatheroma (TCFA) (n¼146 lesions in 135
pts) and non-heterogeneous group (homogenous and layered, n¼346 lesions in 312
pts). The baseline clinical characteristics, angiographic features and OCT ﬁndings
were compared between two groups. The major adverse cardiac events [MACEs,
a composite of cardiac death, non-fatal myocardial infarction (MI), target lesion
revascularization (TLR)] were assessed according to neointimal patterns.
Results: The mean age of heterogeneous group and prevalence of acute coronary
syndrome (ACS) was higher (64.18.9 vs. 61.49.7, p¼0.004 and 60.3% vs. 51.6%,
p¼0.003). Statins were less often used in heterogeneous group (86.9% vs. 93.8%,
p¼0.016). The heterogeneous group showed a signiﬁcantly higher frequency of bare
metal stents (BMSs) (5.6% vs. 0.9%, p<0.001), and 1st generation drug-eluting stents
(DESs) (49.3% vs. 37.3%, p¼0.016). Compared with non-heterogeneous, heteroge-
neous group had a longer time interval after stenting (33.4 42.2 vs. 16.222.3
months, p<0.001). In multivariate analysis, the most signiﬁcant determinant for the
heterogeneous pattern was the initial ACS diagnosis (odds ratio [OR] ¼2.13, 95%
conﬁdence interval [CI]¼1.28-3.54, p¼0.004). The MACEs occurred more frequently
in the heterogeneous group (14.9% for 4-years vs. 4.7%, p<0.001). A multivariate Cox
regression analysis also showed that heterogeneous neointimal types could be an
independent risk factor (hazard ratio [HR] ¼3.23, 95% CI¼ 1.34 – 7.82, p¼0.009).
Conclusions: The neointimal characteristics could be helpful to predict long-term
clinical outcomes. Especially, heterogeneous neointimal pattern might be related with
a poor clinical prognosis.
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Background: Dual antiplatelet therapy (DAPT) is utilized for varying durations
following drug-eluting stent (DES) implantation in patients with stable coronary artery
disease, largely based on concerns of stent thrombosis (ST). A prior analysis of 5371
patients undergoing Resolute zotarolimus-eluting stent (R-ZES) implantation found
that the greatest risk of ST occurred in the ﬁrst month after the procedure if DAPT was
interrupted. We sought to extend this analysis.
Methods: A patient-level analysis of all available Resolute zotarolimus-eluting stent
(R-ZES) studies (n¼8) was conducted. Rates of ARC deﬁnite/probable ST at one year
were examined as a function of whether DAPT was interrupted prior to ST for more
than 1 day within the ﬁrst month or between 1 and 12 months after stent placement.
Results: There were a total of 7131 patients eligible for the DAPT analysis; 1315
(18%) had an interruption of DAPT during the ﬁrst 12 months post R-ZES implan-
tation. Of those 1315 patients, 221 (17%) had the DAPT interruption in the ﬁrst month
and 1094 (83%) between 1-12 months post DES. The baseline characteristics of the
patients with DAPT interruption were notable for a median age of 66 years, with 32%
having diabetes and 45% with an acute coronary syndrome (15% biomarker positive,
31% with unstable angina); the mean number of stents placed was 1.6, the mean total
stent length was 31 mm, and the mean stent diameter per stent was 2.9 mm. The
overall rate of stent thrombosis within 12 months was 0.7% (50/7131). The 12-month
rate of ST with DAPT interruption in the ﬁrst month was 3.2% (7/221) and 0.1% (1/
1094) with DAPT interruption in the >1-12 month group. The rate of ST over 12
months in patients with no DAPT interruption was 0.7% (42/5816).
Conclusions: In this larger pooled analysis of patients undergoing R-ZES placement,
the 12-month rate of ST was 0.7%, with the majority of ST events occurring during
the ﬁrst month after stent implantation. There was no apparent increased risk for ST in
patients who needed to interrupt DAPT after the ﬁrst month post R-ZES placement.B144 JACC Vol 62/18/Suppl B j October 27–November 1, 20TCT-472
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Background: Presence of stent fracture (SF) after sirolimus-eluting stent (SES)
implantation has reported to be associated with an increased risk of in-stent restenosis
and target lesion revascularization (TLR). Incidence of SF and the relevance to
cardiovascular events are previously reported. But little is known about the outcomes
after repeat percutaneous coronary intervention (PCI) for SES restenosis lesion with
SF. So this study compared the outcomes after repeat PCI for SES restenosis lesion
with or without SF.
Methods: From April 2007 to September 2011, total 2020 lesions implanted SES
during PCI at our hospital. Total 148 lesions, 7.3% had restenosis (deﬁned as %
diameter stenosis >50%) in follow up angiogram. Of the restenosis lesion, 107 lesions
went to TLR those consisted of 75 lesions with repeat DES implantation and 32
lesions with balloon angioplasty alone. SF was deﬁned as complete or partial sepa-
ration of the stent as assessed by plain ﬂuoroscopy and detected in 61 lesions of SES
restenosis lesions. Thirty-three SES restenosis lesions with SF (SF group) and 42 SES
restenosis lesions without SF (non SF group) were retrospectively evaluated re-
restenosis rate during follow up after repeated implantation of DES.
Results: Baseline characteristics were similar. One-year cumulative incidence of re-
restenosis after repeat DES implantation for SF group and non SF group which
calculated by Kaplan-Meier method were 68% and 36% (Log-rank test P¼0.0332),
respectively (ﬁgure).Conclusions: Restenosis lesions with SF had signiﬁcantly high incidence of re-
restenosis after repeat DES implantation.
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Background: Platelets and nitric oxide system play an important role in coronary
disease. Platelet and eNOS polymorphism could be asociated with stent restenosis and
coronary events.
Methods: We included 92 patients (pts) with previous PCI referred to cath lab. We
consider cases pts with conﬁrmed angiographic restenosis (50%)and control pts
without restenosis. Polymerase chain reaction (PCR) was performed for PlA2;
Glu298Asp, -786T>C, 922A/G, intronic 420/393 polymorphisms. A 5 years FU was
done in 96% of pts. A multiple logistic regression analysis with clinical, angiographic
and genetic features was performed.
Results: 92 pts were included: 41 with restenosis and 51 without restenosis. Age,sex
and coronary risk factors were similar in both groups. We use near 60% of DES in
both groups. The genotype distribution is shown in the table. Pts with PlA2 poly-
morphism had a signiﬁcantly higher restenosis rate than those without this
allele(21.9% vs. 1.9%, OR:14.1, 95%CI:1.7-116.3, p¼0.002). Similarly was observed
in patients with 922A/G (41.5% vs. 19.6%, OR:2.9, 95%CI:1.2-7.4, p¼0.02).
Restenosis and events where similar in pts with 298Asp allele, Glu298Asp, intronic
420/393 and -786T>C polymorphism. In the multivariate analysis the PlA1/A2
remains as the only independent predictor of restenosis. At 5 years FU, the cardiac
events rate was: death 12%, new restenosis 8.0%, hospitalization 31.8%, non target
lesion revascularization (TLR) 12.5%, with no differences within groups. Only the
PLA2 was associated with non TLR at 5 years FU (36.4% vs. 7.8%, p¼0.005).13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
